Analysts Anticipate Minerva Neurosciences Inc (NERV) Will Announce Earnings of -$0.37 Per Share

Analysts forecast that Minerva Neurosciences Inc (NASDAQ:NERV) will post earnings of ($0.37) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences reported earnings per share of ($0.28) during the same quarter last year, which suggests a negative year over year growth rate of 32.1%. The business is scheduled to report its next earnings report on Monday, November 5th.

On average, analysts expect that Minerva Neurosciences will report full year earnings of ($1.39) per share for the current year. For the next fiscal year, analysts anticipate that the business will report earnings of ($1.56) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06.

Several research firms have issued reports on NERV. BidaskClub upgraded Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. ValuEngine upgraded Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 23rd. Finally, Citigroup boosted their price target on Minerva Neurosciences to $19.00 in a research note on Friday, August 3rd.

In other news, COO Joseph H. Reilly sold 25,000 shares of the business’s stock in a transaction dated Thursday, August 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the sale, the chief operating officer now owns 39,177 shares in the company, valued at $391,770. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William F. Doyle purchased 4,000 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $39,520.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $39,520. The disclosure for this purchase can be found here. Insiders have bought 8,000 shares of company stock worth $81,520 in the last 90 days. Insiders own 9.60% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Northern Trust Corp grew its stake in shares of Minerva Neurosciences by 18.7% during the second quarter. Northern Trust Corp now owns 358,803 shares of the biopharmaceutical company’s stock worth $2,960,000 after acquiring an additional 56,592 shares during the last quarter. Millennium Management LLC grew its stake in shares of Minerva Neurosciences by 2.8% during the second quarter. Millennium Management LLC now owns 919,471 shares of the biopharmaceutical company’s stock worth $7,586,000 after acquiring an additional 25,092 shares during the last quarter. MetLife Investment Advisors LLC purchased a new stake in shares of Minerva Neurosciences during the second quarter worth about $135,000. Renaissance Technologies LLC boosted its position in Minerva Neurosciences by 241.1% in the second quarter. Renaissance Technologies LLC now owns 176,000 shares of the biopharmaceutical company’s stock valued at $1,452,000 after buying an additional 124,400 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Minerva Neurosciences by 40.4% in the second quarter. Dimensional Fund Advisors LP now owns 391,041 shares of the biopharmaceutical company’s stock valued at $3,226,000 after buying an additional 112,461 shares during the last quarter. Institutional investors and hedge funds own 71.96% of the company’s stock.

NERV traded down $0.30 on Friday, hitting $11.90. The company had a trading volume of 10,253 shares, compared to its average volume of 202,862. Minerva Neurosciences has a 12-month low of $4.80 and a 12-month high of $12.35. The firm has a market capitalization of $430.39 million, a PE ratio of -11.30 and a beta of 1.63.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Read More: What Does Beta Mean In Stock Selection

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply